Ulcer

BREAKTHROUGH IN DIGITAL HEALTH: WITHINGS HEALTH SOLUTIONS LAUNCHES BODY PRO 2, REVOLUTIONIZING THE DETECTION OF EARLY DIABETES COMPLICATIONS WITH THE NEXT-GEN CELLULAR SCALE

Retrieved on: 
Tuesday, November 14, 2023
Motivation, ESC, Research, Activator (genetics), Diabetic foot, Risk, Body, Patient, Weather, Nature, Withings, Ulcer, Type 2 diabetes, Electrochemical skin conductance, Forecasting, Body composition, DPN, LCD, Biomarker, Diabetes, Pharmaceutical industry, Mobile phone, Medical device

BOSTON, Nov. 14, 2023 /PRNewswire/ -- Today, on World Diabetes Day, Withings Health Solutions provides a leap forward for the digital health industry with the launch of Body Pro 2, a revolutionary device redefining the nature and use of cellular-connected smart scales. Body Pro 2 is the result of years of research and development, consultation with hundreds of digital health partners and clinicians, and embodies Withings' vision that digital health needs to be a better experience for all stakeholders. It combines habit-forming user features with a pioneering modular approach to manage chronic conditions within one versatile device. Its core capabilities allow care teams to capture advanced health metrics such as weight and body composition while additional and optional health modules unlock the ability to track advanced and clinically validated biomarkers typically only available in a professional setting.  

Key Points: 
  • Prevention of type 2 diabetes and diabetes-related complications is the focus of the final year of the World Diabetes Day 2021-23 theme, Access to Diabetes Care.
  • Body Pro 2's first module is prescription-only (Rx) and aims to improve the way patients with diabetes are taken care of.
  • With this module care teams can monitor one of the biggest challenges in diabetes, diabetic foot health, which is often overlooked.
  • 1
    With Body Pro 2, Withings Health Solutions reinforces its value proposition to the digital health industry.

Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 9, 2023
Research, United European Gastroenterology, American College, NLRX1, UC, D&O, Biomarker, NEXUS, ACG, Wind, American College of Gastroenterology, D, Poster, Ulcerative colitis, Inflammatory bowel disease, LTE, UZ Leuven, KU Leuven, Pharmacokinetics, Clinical trial, Epithelium, Ulcer, Safety, Patient, Gene expression, Pharmaceutical industry

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the quarter ended September 30, 2023.

Key Points: 
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the quarter ended September 30, 2023.
  • NEXUS Phase 2 proof-of-concept clinical trial:
    The NEXUS trial of NX-13 remains on track as the Company continues to recruit, screen and randomize patients for the trial.
  • Research and development expenses were $3.1 million for the third quarter of 2023, compared to $4.9 million for the third quarter of 2022.
  • General and administrative expenses were $2.1 million for the third quarter of 2023, compared to $3.0 million for the third quarter of 2022.

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Retrieved on: 
Monday, November 6, 2023
FDA, Arm, Multinational, Food, Therapy, PG, Biotechnology, MD, European Medicines Agency, Ulcer, OD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clutch (eggs), Phase, EMA, Phase III offensive, Safety, Patient, Pyoderma, Neutrophil, Pharmaceutical industry

“We are pleased that the first patient has been dosed in the U.S. in our pivotal Phase III study with vilobelimab for the treatment of ulcerative pyoderma gangrenosum.

Key Points: 
  • “We are pleased that the first patient has been dosed in the U.S. in our pivotal Phase III study with vilobelimab for the treatment of ulcerative pyoderma gangrenosum.
  • In both arms, corticosteroid treatment will be initiated on day 1 and will be tapered off within the first 8 weeks of the trial.
  • The primary endpoint of the study is complete closure of the target ulcer at any time up to 26 weeks after initiation of treatment.
  • The enrollment period is projected to last at least two years, and its overall period will depend on the total trial size after sample size adaptation.

UK Leads European Medical Tapes & Wraps Market with 21% Share, Driven by Rising Chronic Diseases - ResearchAndMarkets.com

Retrieved on: 
Monday, November 6, 2023
Hospitals, Health, Medical Supplies, Ulcer, Trauma, Prevalence, Conditional sentence, Diabetes, Hospital, Accident, Cancer, European Wound Management Association, Medical device

The European medical tapes & wraps market is poised for substantial growth, with an expected CAGR of 3.64%, reaching $3.46 billion by 2028 from $2.79 billion in 2022.

Key Points: 
  • The European medical tapes & wraps market is poised for substantial growth, with an expected CAGR of 3.64%, reaching $3.46 billion by 2028 from $2.79 billion in 2022.
  • This market analysis report provides comprehensive insights into the European medical tapes & wraps market, covering market size, forecasts, segmentations, and industry trends.
  • UK Dominance: In 2022, the UK emerged as the market leader, accounting for over 21.00% of the European market share.
  • The European medical tapes & wraps market features a wide array of prominent vendors, including:

'Listen to your patients for early identification of Peripheral Neuropathy' say leading Health Experts at P&G's #KNOWTHESIGNS Scientific Forum

Retrieved on: 
Monday, November 6, 2023
Global Medical Device Nomenclature, Patient, Ulcer, Education, PN, Prickle (protein), Neuropathic pain, Neurology, Assistant, Facial muscles, Physician, Prevalence, IDF, Burning Sensations, Health, International Diabetes Federation, DPN, Type 2 diabetes, WDD, Finger, Foot, Hypoesthesia, Senior, AMA, Prediabetes, Paresthesia, Quality of life, Bethesda Hospital, The, Extremities, Risk, P&G, Peripheral neuropathy, Lyceum, Trial of the century, B, Pharmacist, Ankle, Amputation, Diagnosis, Consultant, Infection, Dietary supplement, Pharmaceutical industry, Diabetes

The signature event saw deliberations on the latest clinical guidance on diagnoses and treatment of Peripheral Neuropathy (PN) in Diabetes and Pre-Diabetes.

Key Points: 
  • The signature event saw deliberations on the latest clinical guidance on diagnoses and treatment of Peripheral Neuropathy (PN) in Diabetes and Pre-Diabetes.
  • With Diabetes Mellitus Type 2 being the leading cause of PN, its increasing prevalence is closely linked to the rise in the number of diabetics.
  • B vitamin deficiency and polymedication are other high-risk factors along with diabetes, leading to peripheral nerve damage.
  • Patients should be educated about the importance of regular foot and DPN examinations, glycemic control, and adherence to prescribed medications.

First Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Tuesday, October 31, 2023
Atheroma, Peripheral artery disease, Diabetes, Pivotal trial, Ulcer, Transducer, Male, Disease, PAP, Buerger's test, Classification, The Unreconstructed M, IVUS, Amputation, Stent, PAD, PP, Thorpe tube flowmeter, TUS, Calf, Chin Na, Vein, Telephone, TASC, Bare, Vibrato, Life, SP, W. L. Gore & Associates, VIVA, Safety, Patient, Dyslipidemia, Blood vessel, Plaque, History, CLTI, Coronary artery disease, Perfusion, Restenosis, Research, Foot, Spur, Atherectomy, Șaeș, Artery, Education, DCB, Doppler effect, Dialysis, Hypertension, FP, Freedom, Wynn Las Vegas, Wound healing, Medical imaging, Pharmaceutical industry, Birth control, Surveying, Medtronic

Below are highlights of this morning's 5 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 5 late-breaking clinical trial presentations.
  • At 20 centers without roll-ins across the United States, 105 no-option CLTI patients were enrolled in a nonrandomized manner.
  • The median age was 70 years, two-thirds of the patients were male, and one-quarter of patients were Hispanic or Latino.
  • 1-Year Results of the DEEPER OUS Trial: The Bare Temporary Spur Stent System in Combination With a Paclitaxel-Coated Balloon
    The DEEPER OUS trial is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland.

Groundbreaking Study Reveals the Effectiveness of New RecoSMA Laser Treatment for Diabetic Foot

Retrieved on: 
Friday, October 27, 2023
Ulcer, Hope, Diabetes, Fibrosis, Statistics, Erbium, International Diabetes Federation, Research, Journal, Foot, Amputation, Quality of life, Rehabilitation, Regeneration, YAG, Knee, Patient, Wound, Wound healing, Pharmaceutical industry, Medical imaging

LONDON, Oct 27, 2023 - (ACN Newswire) - LINLINE MEDICAL SYSTEMS, based in Riga, Latvia, has demonstrated the remarkable effectiveness of its distinctive RecoSMA laser technology in treating chronic wounds.

Key Points: 
  • LONDON, Oct 27, 2023 - (ACN Newswire) - LINLINE MEDICAL SYSTEMS, based in Riga, Latvia, has demonstrated the remarkable effectiveness of its distinctive RecoSMA laser technology in treating chronic wounds.
  • The recent study, "Spatially modulated erbium YAG laser as a treatment for diabetic ulcer", published in the Journal of Wound Care (UK), was conducted using a MULTILINE laser system produced by the company.
  • RecoSMA for Chronic Ulcers - Chronic ulcers treatment: a two-step approach
    The study, conducted by a team of esteemed researchers, aimed to address the pressing issue of diabetic foot complications, which affect a substantial portion of the global population.
  • In this landmark study, researchers explored the use of a novel laser treatment for diabetic foot ulcers designed to revolutionize how we approach this chronic problem.

The International Diabetic Lower Extremity Symposium of the International Society of Regenerative Medicine and Wound Repair Held

Retrieved on: 
Thursday, October 26, 2023
Denver 2008 Convention Host Committee, Ulcer, Regenerative medicine, Health, Asia-Pacific Economic Cooperation, Research, Speech, Partnership, APEC, International Society, International Diabetes Center at Park Nicollet, Pharmaceutical industry, Veterinary medicine

PHUKET, Thailand, Oct. 25, 2023 /PRNewswire/ -- During the period from October 25 to 27, 2023, the International Diabetic Lower Extremity Symposium of the International Society of Regenerative Medicine and Wound Repair is held in Thailand.

Key Points: 
  • PHUKET, Thailand, Oct. 25, 2023 /PRNewswire/ -- During the period from October 25 to 27, 2023, the International Diabetic Lower Extremity Symposium of the International Society of Regenerative Medicine and Wound Repair is held in Thailand.
  • As the Asia-Pacific Economic Cooperation (APEC) Summit is coming, Kevin Xu, President of the International Society of Regenerative Medicine and Wound Repair and co-chair of the APEC 2023 Host Committee, attended the meeting.
  • In his speech, he highlighted the importance of regenerative medicine and wound repair, especially the key role in dealing with problems such as diabetic foot ulcers.
  • The International Society of Regenerative Medicine and Wound Repair, established in 2018, has always been committed to promoting the integration and transformation of basic research and clinical applications of regenerative medicine, building a platform for global collaborative development and innovative cooperation in regenerative medicine, and giving play to the advantages of regenerative medicine in promoting human health.

Spectral AI Provides 2023-2024 Annual Revenue Guidance

Retrieved on: 
Monday, October 23, 2023
Government, 3D, FDA, Ulcer, History, Physician, CE, UKCA, Spectral, MDAI, Research, Artificial intelligence, DFU, Burn, Patient, Diagnosis, Wound healing, Medical device

DALLAS, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today provided annual revenue guidance for the fiscal years ending December 31, 2023 and 2024 and highlighted plans and opportunities associated with the ongoing development and commercialization of its AI-Driven DeepView® Wound Imaging Technology for diabetic foot ulcers (“DFU”), burn and other indications.

Key Points: 
  • DALLAS, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today provided annual revenue guidance for the fiscal years ending December 31, 2023 and 2024 and highlighted plans and opportunities associated with the ongoing development and commercialization of its AI-Driven DeepView® Wound Imaging Technology for diabetic foot ulcers (“DFU”), burn and other indications.
  • The Company recently announced the largest contract in its history, an award from the U.S. Government valued at over $149.0 million, which brings the total U.S. Government awards to the Company since 2019 to over $246.0 million.
  • With this contract in hand, the Company now has far greater visibility into its research and development revenues for 2023 and 2024 and is pleased to provide this information to the Company’s shareholders.
  • “We are on the cusp of delivering a distinct, cutting-edge AI-driven wound healing assessment platform with the potential to significantly improve the current standard of care across multiple indications,” said Wensheng Fan, CEO of Spectral AI.

CHINA NEW ENERGY GROUP COMPANY/THRIVE PRECISION HEALTH ANNOUNCES BINDING AGREEMENT TO ACQUIRE TWO DIABETES CLINICS IN ARIZONA

Retrieved on: 
Wednesday, October 25, 2023
Science, Arizona Department of Health Services, History, Ulcer, Health care, IV, Medicare, Personalized medicine, Thrive, EBITDA, Diabetes, Acquisition, Prediabetes, Dialysis, Amputation, Arizona Department, Patient, Letter, Pharmaceutical industry, Medicaid

SPOKANE, Wash., Oct. 25, 2023 /PRNewswire/ -- Thrive Precision Health ("THRV") (formerly Thrive Global Biosafety and China New Energy Group Company (with subsidiary Thrive Testing and Biosafety Inc., "CNER" or "Company") (OTC-Pink-Alternative Reporting Pink: CNER) is pleased to announce it has entered into a binding letter of intent to acquire two diabetes clinics on Arizona.

Key Points: 
  • " To us, the words Precision Health and Personalized Medicine mean better outcomes by tailoring our approach and offering individualized treatment to every patient using proven science.
  • We will continue to acquire or start new specialized diabetes clinics in Arizona with a goal of thirty more sites".
  • The Arizona Department of Health Services, in their Published Diabetes Action Plan and Report 2023, states that yearly direct and indirect costs of diabetes in Arizona exceed $6.8 billion.
  • During this hold period, THRV will advance funds to True Diabetes to continue expanding their operations in both locations.